In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...

In 2025, Anthropic will grow from $1 billion to $9 billion in ARR (annual recurring revenue). OpenAI, meanwhile, will go from ...

Cornered in a part of Downtown Los Angeles swamped in contemporary art museums and performance centers, REDCAT has become a ...

Biopharma may see a happier year ahead in 2026 than in recent years, according to analysts at William Blair. For one thing, the industry’s top stocks have recovered from lows that stretched into last ...

A steaming bowl of pho becomes the most vivid thing in your visual field – the clear amber broth, bright green herbs, ruby red sriracha swirls, and sunny yellow lime wedges appearing almost ...

The new major version with a new JIT compiler, a revised parallelization API, and a maturing type system paves the way for ...